Eventide Healthcare & Life Sciences Fd Cl N
ETNHX
NASDAQ- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 4221 North 203rd Street, Suite 100 Elkhorn NE United States of America 68022-3474
- IPO Date
- Dec 27, 2012
- CIK
- 0001355064
- Website
- eventideinvestments.com
- Similar Companies
- Business
- Eventide Healthcare & Life Sciences Fund Class N (ETNHX) is a diversified mutual fund that seeks long-term capital appreciation by investing at least 80% of its net assets in equity and equity-related securities of companies in the healthcare and life sciences sectors, with a concentration of at least 25% in drug-related industries; it may allocate up to 15% to illiquid securities, including private investments, IPOs, and mezzanine financing offerings. The fund targets early development-stage companies addressing unmet medical needs, such as rare and orphan diseases, through therapies for pulmonary infections, pediatric cholestasis, cancer diagnostics, neuromuscular disorders, neurological and psychiatric conditions, autoimmune diseases, and cardiac arrhythmia detection; top holdings as of late 2025 include Insmed Inc., Mirum Pharmaceuticals Inc., Guardant Health Inc., Axsome Therapeutics Inc., and Alnylam Pharmaceuticals Inc., with a median market capitalization of approximately $2.4 billion and an average of $9.3 billion across 71 holdings. Launched on December 27, 2012, by Eventide Asset Management LLC, headquartered in Boston, Massachusetts, the fund operates primarily in U.S. markets but invests without limitation in foreign-domiciled companies via American Depositary Receipts, serving individual and institutional investors focused on healthcare innovation. Recent developments include the addition of I-hung Shih, PhD, as co-portfolio manager in September 2024 alongside lead manager Finny Kuruvilla, MD, PhD, enhancing the team's expertise in biotech private investments; Eventide closed its inaugural Eventide Healthcare Innovation Fund I, LP, with $83 million in commitments in May 2024 to target private biotech firms within three years of value milestones; and the firm launched three new systematic ETFs in September 2025, expanding its product suite while maintaining a focus on ethical, sustainable practices. As of December 2025, the fund manages approximately $1.66 billion in assets, with Class N shares featuring a 1.52% expense ratio, no front-end load, and annual distributions.